RNAC — Cartesian Therapeutics Share Price
0.000.00%
Last trade - 00:00- $272.02m
- $59.41m
- $38.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.99 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.65% | ||
| Return on Equity | n/a | ||
| Operating Margin | -112.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16.6 | 85.08 | 110.78 | 26 | 38.91 | 3.33 | n/a | 42.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Directors
- Carrie Cox NEC (64)
- Carsten Brunn PRE (50)
- Kevin Tan CFO (44)
- Lloyd Johnston COO (53)
- Kristen Baldwin CHO
- Takashi Kishimoto CSO (61)
- Peter Traber OTH (66)
- Nishan de Silva DRC
- Goran Ando IND (72)
- Timothy Barabe IND (68)
- Scott Myers IND (55)
- Aymeric Sallin IND (47)
- Timothy Springer IND (72)
- Patrick Zenner IND (74)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 10th, 2007
- Public Since
- June 22nd, 2016
- No. of Shareholders
- 107
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 25,907,101
- Address
- 7495 New Horizon Way, FREDERICK, 21703
- Web
- https://www.cartesiantherapeutics.com/
- Phone
- +1 3013488698
- Contact
- Ron Moldaver
- Auditors
- Ernst & Young LLP
Upcoming Events for RNAC
Cartesian Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Cartesian Therapeutics Inc Earnings Release
Similar to RNAC
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Cartesian Therapeutics share price?
As of Today at 19:49 UTC, shares in Cartesian Therapeutics are trading at $10.50. This share price information is delayed by 15 minutes.
How has the Cartesian Therapeutics share price performed this year?
Shares in Cartesian Therapeutics last closed at $10.50 and the price had moved by -43.24% over the past 365 days. In terms of relative price strength the Cartesian Therapeutics share price has underperformed the S&P500 Index by -46.63% over the past year.
What are the analyst and broker recommendations for Cartesian Therapeutics?
The overall consensus recommendation for Cartesian Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cartesian Therapeutics dividend yield?
Cartesian Therapeutics does not currently pay a dividend.
Does Cartesian Therapeutics pay a dividend?
Cartesian Therapeutics does not currently pay a dividend.
When does Cartesian Therapeutics next pay dividends?
Cartesian Therapeutics does not currently pay a dividend.
How do I buy Cartesian Therapeutics shares?
To buy shares in Cartesian Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cartesian Therapeutics?
As of the previous close price of $10.50, shares in Cartesian Therapeutics had a market capitalisation of $272.02m.
Where are Cartesian Therapeutics shares listed?
Here are the trading details for Cartesian Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RNAC
What kind of share is Cartesian Therapeutics?
Based on an overall assessment of its quality, value and momentum Cartesian Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cartesian Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Cartesian Therapeutics is $39.14. That is 272.76% above the last closing price of $10.50.
Analysts covering Cartesian Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.05 for the next financial year.
Find out moreWhat is the trend in the Cartesian Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cartesian Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -49.12%.
As of the last closing price of $10.50, shares in Cartesian Therapeutics were trading -39.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cartesian Therapeutics PE Ratio?
The Cartesian Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cartesian Therapeutics?
Cartesian Therapeutics' management team is headed by:
- Carrie Cox - NEC
- Carsten Brunn - PRE
- Kevin Tan - CFO
- Lloyd Johnston - COO
- Kristen Baldwin - CHO
- Takashi Kishimoto - CSO
- Peter Traber - OTH
- Nishan de Silva - DRC
- Goran Ando - IND
- Timothy Barabe - IND
- Scott Myers - IND
- Aymeric Sallin - IND
- Timothy Springer - IND
- Patrick Zenner - IND